Research Progress of PI3K/AKT/mTOR Signaling Pathway in Targeted Therapy for Triple-negative Breast Cancer
Triple-negative breast cancer(TNBC)is an important subtype of breast cancer,because of its triple-negative characteristics,the molecular targeted therapy effect is poor,and neoadjuvant chemotherapy is used in the clinic to treat TNBC,but the efficacy is general and the prognosis is poor.The phosphatidylositol 3-kinase/protein kinase B/mammalian rapamycin target(PI3K/AKT/mTOR)signaling pathway,and depolymer-metalloproteinase 17(ADAM17)have abnormal activation states in a variety of tumors and are important anti-tumor targets.In this paper,combined with the relevant literature in recent years,the research on the PI3K/AKT/mTOR signaling pathway,and ADAM17 in tumorigenesis,related targets and TNBC targeted therapy is summarized and analyzed,in order to provide new ideas for the multi-target combination therapy of TNBC.
PI3K/AKT/mTOR signaling pathwayDepolymerin-metalloproteinase 17Triple-negative breast cancerTargeted therapy
国家科技期刊平台
NSTL
万方数据
维普
